Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies
D Wu, Q Sun, H Tang, H Xiao, J Luo, L Ouyang… - Drug Resistance …, 2024 - Elsevier
Over the past two decades, tyrosine kinase inhibitors (TKIs) have rapidly emerged as pivotal
targeted agents, offering promising therapeutic prospects for patients. However, as the …
targeted agents, offering promising therapeutic prospects for patients. However, as the …
The prospect of substrate-based kinase inhibitors to improve target selectivity and overcome drug resistance
Human kinases are recognized as one of the most important drug targets associated with
cancer. There are> 80 FDA-approved kinase inhibitors to date, most of which work by …
cancer. There are> 80 FDA-approved kinase inhibitors to date, most of which work by …
Recent advances in the treatment of non-small cell lung cancer with MET inhibitors
D Zhang, W Zhang, H Liu, P Liu, C Li, Y Liu… - Frontiers in …, 2024 - frontiersin.org
Recently, research into the oncogenic driver genes associated with non-small cell lung
cancer (NSCLC) has advanced significantly, leading to the development and clinical …
cancer (NSCLC) has advanced significantly, leading to the development and clinical …